Phillip Coffin

Phillip O. Coffin, M.D., M.I.A., F.A.C.P., is the Director of Substance Use Research at the San Francisco Department of Public Health. He is board-certified in internal medicine, infectious diseases, and addiction medicine; specific foci of Dr. Coffin’s training include general infectious diseases, HIV and viral hepatitis, buprenorphine maintenance, addiction management, and drug poisoning. As Director, Dr. Coffin oversees several pharmacologic and behavioral trials that aim to reduce substance use and related risk behaviors for blood-borne virus infection, as well as related observational studies. Since the early 1990s, Dr. Coffin has been involved in developing and studying services for drug users, including syringe exchange, pharmacotherapy, and overdose prevention programming.

Dr. Coffin completed his undergraduate studies at Brown University, graduate studies in international affairs at Columbia University, and obtained his medical degree at the University of California, San Francisco. He returned to Columbia University to complete his internal medicine residency, then moved to Seattle to complete his training with an infectious diseases fellowship at the University of Washington.

Dr. Coffin’s interests include development of pharmacotherapies for substance use disorders; drug overdose, with an emphasis on opioid safety and the provision of naloxone; mathematical modeling of substance use and infectious diseases; and clinical care for HIV, viral hepatitis, and general infectious diseases. Dr. Coffin has an established record of clinical experience, academic service, innovative research, and mentoring.

How Long Does THC Stay in the Body

Dr. Coffin studied overdose prevention. In this case drugs stay in your system for a long time. And many people in the US wonder – how long does THC stay in the body? This question is important to pass a drug test successfully.

There are various drug tests – hair, urine, saliva, and blood tests. If you’re wondering, “how long does it take weed to leave system,” there is no definite answer as it differs for each individual. The average THC detection time differs for these tests, and to pass them successfully you should know, how the body metabolizes THC.


Selected Publications:

  1. Martin JM, Patrick SL, Coffin PO, Tsou K, Walker JM. An examination of the central sites of action of cannabinoid-induced antinociception in the rat. Life Sci. 1995;56:2103-9. PMID 7776838
  2. Attias E, Balinsky M, Coffin P, Martin W, Walker M. The identification of anatomical sites of cannabinoid-induced antinociception. Society for Neuroscience Abstracts. 1997;23(1-2):159
  3. Grund J-PC, Coffin PO. Inovativna politika kot odgovor na porajajoce se probleme v zvezi z drogami in AIDS-om v Srednji in Vzhodni Evropi: paradigma zmanjsevanja skode (Innovative policy responses to emerging drugs and AIDS problems in Central and Eastern Europe and the newly independent states: the harm reduction paradigm). In Dekleva B, Grund J-PC, Nolimal D (eds.) Paradigma zmanjsevanja skode kot politika droge. Revija MREZA DROG, 1997, 5(2-4), 8-19.
  4. Coffin PO. Kokain in nosecnost: osnovna dejstva (Cocaine and pregnancy: Basic facts). In Dekleva B, Grund J-PC, Nolimal D (eds.) Paradigma zmanjsevanja skode kot politika droge. Revija MREZA DROG, 1997, 5(2-4), 20-30.
  5. Dixon D, Coffin P. Zero tolerance policing of illegal drug markets. Drug Alcohol Rev. 1999 Dec;18(4):477-86.
  6. Martin WJ, Coffin PO, Attias E, Balinsky M, Tsou K, Walker JM. Anatomical basis for cannabinoid-induced antinociception as revealed by intracerebral microinjections. Brain Res. 1999;822(1-2):237-42. PMID 7776838
  7. Coffin PO, Linas BP, Factor SH, Vlahov D. New York City pharmacists’ attitudes toward sale of needles/syringes to injection drug users before implementation of law expanding syringe access. Journal of Urban Health. 2000;77(4):781-93. PMID 11194317
  8. Linas BP, Coffin PO, Backes G, Vlahov D. New York State pharmacists’ attitudes toward needle and syringe sales to injection drug users before implementation of syringe deregulation. Journal of Urban Health. 2000;77(4); 768-80. PMID 11194316
  9. Coffin PO. Syringe availability as HIV prevention: A review of modalities. Journal of Urban Health. 2000;77(3):302-26. PMID 10976607
  10. Jones TS. Coffin PO. Preventing blood-borne infections through pharmacy syringes sales and safe community syringe disposal. Journal of the American Pharmaceutical Association. 2002;42(Suppl 2):S6-S10.  PMID 12489602
  11. Fuller CM, Ahern J, Vadnai L, Coffin PO, Galea S, Factor S, Vlahov D. Impact of increased syringe access: Preliminary findings on injection drug user syringe source, disposal, and pharmacy sales in Harlem, New York. Journal of the American Pharmaceutical Association. 2002;42(Suppl 2):S77-S82. PMID 12489621
  12. Coffin PO, Ahern J, Dorris S, Stevenson L, Fuller C, Vlahov D. More pharmacists in high-risk neighborhoods of New York City support selling syringes to injection drug users. Journal of the American Pharmaceutical Association. 2002;42(Suppl 2):S62-S67. (see PMID 12489618
  13. Weiss L, Fabri A, McCoy K, Coffin PO, Netherland J, Finkelstein R. A vulnerable population in a time of crisis: Drug users and the attacks on the World Trade Center. Journal of Urban Health. 2002;79(3):392-403. PMID 12200508
  14. Coffin PO. Marketing harm reduction: a historical narrative of the International Harm Reduction Development Program, International Journal of Drug Policy. 2000;13(3):209-20.
  15. Coffin PO, Strodaha A. Overdose in Central and Eastern Europe and the Former Soviet Union. New York: Open Society Institute. June 2002. URL: articles_publications/publications/overdose_20020601/overdose_report_2002.pdf
  16. Galea S, Coffin PO. Drug overdose: New insights, innovative surveillance, and promising interventions (editorial). J Urban Health. 2003;81:186-8. PMID 12791794
  17. Coffin PO, Fuller C, Vadnai L, Blaney S, Vlahov D. Preliminary evidence of healthcare provider support for naloxone prescription as overdose fatality prevention strategy in New York City. J Urban Health. 2003;81:288-90. PMID 12791804
  18. Galea S, Ahern J, Tardiff K, Leon A, Coffin PO, Derr K, Vlahov D. Racial/ethnic disparities in overdose mortality trends in New York City, 1990-1998. J Urban Health. 2003;81:201-11. PMID 12791796
  19. Coffin PO, Galea S, Ahern J, Leon AC, Vlahov D, Tardiff K. Opiates, cocaine and alcohol combinations in drug overdose deaths in New York City, 1990-1998. Addiction. 2003;98:739-47. PMID 12780362
  20. Galea S, Ahern J, Vlahov D, Coffin PO, Fuller C, Leon AC, Tardiff K. Income distribution and risk of fatal drug overdose in New York City neighborhoods. Drug Alcohol Depend. 2003;70:139-48. PMID 12732407
  21. Ciccarone D, Coffin P, Preer G. Integrating HIV risk reduction education into the medical curriculum. Med Educ. 2004 Nov;38(11):1197-8. PMID 15507033
  22. Singleton M, Qin H, Williams P, Coffin PO, Hedegaard H, Meng CK, Mathew T, Gladders B, Dearwater S, Hackman H, Mao C, McKeown L, Sanford C, Jones-Vessey K, Schmid D, Woodard B, Alexander J, Rolfs RT, Sabel J, LeMier M, Lima A, Daniel V, Olson J, Coronado VG, Davies M, Johnson RL, Peterson CA. Unintentional and undetermined poisoning deaths—11 states, 1990-2001. Morbidity and Mortality Weekly Report. 2004 Mar 26;53:233-8. PMID 15041950
  23. Coffin PO, Fuller C, Blaney S, Vadnai L, Miller S, Vlahov D. Syringe distribution to injection drug users for prevention of HIV infection: opinions and practices of health care providers in New York City. Clin Infect Diseases. 2004 Feb 1;38(3):438-41. PMID 14727219
  24. Tracy M, Markham Piper T, Ompad D, Bucciarelli A, Coffin PO, Vlahov D, Galea S. Circumstances of witnessed drug overdose in New York City: Implications for intervention. Drug Alcohol Depend. 2005;79:181-90. PMID 16002027
  25. Galea S, Nandi A, Coffin PO, Tracy M, Markham Piper T, Ompad D, Vlahov D. Heroin and cocaine dependence and the risk of accidental non-fatal drug overdose. J Addict Diseases. 2006;25(3):79-87. PMID 16956872
  26. Coffin PO, Blaney S, Fuller C, Vadnai L, Miller S, Vlahov D. Support for buprenorphine and methadone prescription to heroin-dependent patients among New York City physicians. Amer J Drug Alcohol Abuse. 2006;32(1):1-6. PMID 16450639
  27. Coffin PO, Sharpe B. Cause of death in alcoholic hepatitis (Letter). J Hospital Med. 2007;2(1):51-2. PMID 17295316
  28. Coffin PO. Mortality after release from prison (Letter). New Engl J Med. 2007;356(17):1785. PMID 17465043
  29. Coffin PO, Tracy M, Bucciarelli A, Ompad D, Vlahov D, Galea S. Identifying injection drug users at risk of nonfatal overdose. Acad Emerg Med. 2007 Jul;14(7):616-23. PMID 17554010
  30. Coffin PO, Latka M, Purcell D, Latkin C, Metsch L, Gomez C, Gourevitch M. Safe syringe access is related to safe syringe disposal. AIDS Behav. 2007 Sep;11(5):652-62. PMID 17053854
  31. Coffin, P. Overdose: A Major Cause of Preventable Death in Central and Eastern Europe in Central Asia: Recommendations and Overview of the Situation in Latvia, Kyrgyzstan, Romania, Russia and Tajikistan. Eurasian Harm Reduction Network (EHRN), Vilnius, Lithuania. August 2008. URL:
  32. Coffin PO. Balancing the costs and benefits of opioid analgesics. Public Health. 2009 Feb;123:147-8. PMID 19168193
  33. Gunderson EW, Coffin PO, Chang N, Polydorou S, Levin FR. The interface between substance abuse and chronic pain management in primary care: A curriculum for medical residents. Substance Abuse. 2009 Jul-Sep;30(3):253-60. PMID 19591063
  34. Grund JPC, Coffin P, Jaufreet-Roustide M, Dijkstra M, de Bruin D, Blanken P. “The fast and furious —cocaine, amphetamines and harm reduction.” Harm Reduction: evidence, impacts and challenges. EMCDDA: Lisbon, Portugal. 2010 Apr. pp191-232.
  35. Coffin PO, Sherman S, Curtis M. “Underestimated and overlooked: A global review of drug overdose and overdose prevention.” Cook C, Ed. Global State of Harm Reduction 2010: Key Issues for Broadening the Response. International Harm Reduction Association: London, England. 2010. pp114-20.
  36. Jenkins LM, Banta-Green CJ, Myanard C, Kingston S, Hanrahan M, Merrill JO, Coffin PO. Risk factors for nonfatal overdose at Seattle-area syringe exchanges. J Urban Health. 2011 Feb;88(1):118-28. PMID 21246299
  37. Coffin PO, Stevens AM, Scott JD, Stekler JD, Golden MR. Patient acceptance of universal screening for hepatitis C virus infection. BMC Infectious Diseases. 2011 Jun;11:160. PMID 21645388
  38. Banta-Green CJ, Kuszler PC, Coffin PO, Schoeppe JA. Washington’s 911 Good Samaritan Drug Overdose Law—Initial Evaluation Results. Alcohol & Drug Abuse Institute, University of Washington, November 2011. URL:
  39. Coffin PO, Coffin LS, Murphy S, Jenkins LM, Golden M. Prevalence and characteristics of femoral injection among Seattle-area injection drug users. J Urban Health. 2012 Apr;89(2):365-72. PMID 22391984
  40. Coffin PO, Scott, JD, Golden M, Sullivan SD. Cost-effectiveness and population-level outcomes of general population screening for hepatitis C. Clin Infect Diseases. 2012;54(9):1259-71. PMID 22412061
  41. Peavy KM, Banta-Green CJ, Kingston S, Hanrahan M, Merrill JO, Coffin PO. Hooked on prescription-type opiates prior to using heroin: Results from a survey of syringe exchange clients. J Psychoactive Drugs. 2012;44(3):259-265. PMID 23061326
  42. Coffin PO, Sullivan SD. Cost-effectiveness of naloxone distribution to heroin users for lay overdose reversal. Ann Intern Med. 2013 Jan 1;158(1):1-9. PMID 23277895
  43. Coffin PO, Santos GM, Das M, Santos D, Huffaker S, Matheson T, Gasper J, Vittinghoff E, Colfax G. Aripiprazole for the treatment of methamphetamine dependence: a randomized, double-blind, placebo-controlled trial. Addiction. 2013 Apr;108(4):751-61. PMID 23186131
  44. Santos GM, Coffin PO, Das M, Matheson T, DeMicco E, Raiford J, Vittinghoff E, Dilley J, Colfax G, Herbst J. Dose-response associations between number and frequency of substance use and high-risk sexual behaviors among HIV-negative substance-using men who have sex with men (SUMSM) in San Francisco. Journal of Acquired Immunodeficiency Syndromes. 2013; 63(4):540-544. PMID 23572012
  45. Coffin PO, Sullivan SD. Cost-effectiveness of naloxone distribution to heroin users for lay overdose reversal in Russian cities. Journal of Medical Economics. 2013; 16(8):1051-1060. Doi: 10.3111/13696998.2013.811080. PMID: 23730942
  46. Banta-Green CJ, Beletsky L, Schoeppe JA, Coffin PO, Kuszler PC. Police officers’ experiences with overdose and their knowledge and opinions of Washington State’s drug overdose-naloxone-Good Samaritan law. Journal of Urban Health. 2013; 90(6):1102-11. Doi: 10.1007/s11524-013-9814-y. PMID: 23900788.
  47. Coffin P, Banta-Green C. The dueling obligations of opioid stewardship. Annals of Internal Medicine. 2014; 160(3):207-208. doi:10.7326/M13-2781. PMID: 24322334.
  48. Coffin PO, Santos GM, Colfax G, Das M, Matheson T, DeMicco E, Dilley J, Vittinghoff E, Raiford JL, Carry M, Herbst JH. Adapted Personalized Cognitive Counseling for Episodic Substance-using Men Who Have Sex with Men: A Randomized Controlled Trial. AIDS & Behavior. 2014; 18(7):1390-1400. Doi:10.1007/s10461-014-0712-4. PMID: 24510401.
  49. Santos GM, Coffin PO, Vittinghoff E, Das M, DeMicco E, Matheson T, Raiford J, Dilley J, Colfax G, Herbst J. Substance Use and Drinking Outcomes in Personalized Cognitive Counseling Trial for Episodic Substance-using Men who have sex with Men. Drug and Alcohol Dependence. 2014 Feb 24. pii: S0376-8716(14)00070-2. doi: 10.1016/j.drugalcdep.2014.02.015. PMID: 24641808.
  50. Coffin PO, Banta-Green C. Evidence of harm, risks to inaction. [Letter] Annals of Internal Medicine. 2014 Aug 19; 161(4):307-308. doi: 10.7326/L14-5016-8. PMID: 25133372.
  51. Coffin PO, Reynolds A. Ending hepatitis C in the United States: the role of screening. Hepatic Medicine: Evidence and Research. Invited manuscript; 2014 Jul 3;6:79-87. DOI: 10.2147/HMER.S40940. PMID:25114602.
  52. Hermanstyne K, Santos GM, Vittinghoff E, Santos D, Colfax G, Coffin P. Event-Level Relationship between Methamphetamine Use Significantly Associated with Non-adherence to Pharmacologic Trial Medications in Event-Level Analyses. Drug and Alcohol Dependence. 2014 Oct 1; 145:277-280. doi: 10.1016/j.drugalcdep.2014.07.031. PMID: 25156227.
  53. Coffin PO, Jin H, Huriaux E, Mirzazadeh A, Raymond HF. Trends in health for persons who inject drugs in San Francisco: results from National HIV Behavioral Surveillance 2005-2012. Drug and Alcohol Dependence. 2015 Jan 1;146:45-51. Doi:10.1016/j.drugalcdep.4014.10.025. PMID: 25468816; Corrigendum issued May 2015.
  54. Behar E, Santos M, Rowe C, Wheeler E, Coffin PO. Brief education is sufficient for naloxone distribution to opioid users. Drug and Alcohol Dependence. 2015 Mar 1;148:209-12. doi: 10.1016/j.drugalcdep.2014.12.009. PMID: 25595053.
  55. Davis CS, Banta-Green CJ, Coffin P, Dailey MW, Walley AY. Intranasal Naloxone for Opioid Overdose Reversal. Prehospital Emergency Care. 2015 January-March;19(1):135-137. Epub 2014 Aug 25. PMID: 25153260
  56. Dacarett-Galeano DJ, Santos GM, Santos D, Das M, Coffin PO. Spatial and neighborhood-level correlates of retention in pharmacologic efficacy trials. Drug and Alcohol Dependence. 2014;140:e42. DOI:10.1016/j.drugalcdep.2014.02.137.
  57. Coffin PO, Rowe C, Santos GM. Novel Interventions to prevent HIV and HCV among persons who inject drugs. Current HIV/AIDS Rep 2015 Mar;12(1):145-63. Doi:10.1007/s11904-014-0248-2. PMID: 25589380.
  58. Rowe C, Santos M, Wheeler E, Vittinghoff E, Davidson P, Coffin PO. Predictors of participant engagement and naloxone utilization in a community-based naloxone distribution program. Addiction. 2015 Aug;110(8):1301-10. DOI:10.1111/add.12961. PMID: 25917125.
  59. Walley AY, Krupitsky E, Cheng DM, Quinn EK, Wulach L, Coffin PO, Samet JH. Fatal and non-fatal overdose after narcology hospital discharge among HIV-infected Russians. Drug and Alcohol Dependence. 2015;146:e15. DOI:10.1016/j.drugalcdep2014.09.722.
  60. Visconti A, Santos G-M, Lemos N, Burke C, Coffin PO. Opioid Overdose Deaths in the City and County of San Francisco: Prevalence, Distribution, and Disparities. Journal of Urban Health. 2015. June 16. Epub ahead of print. PMID 26077643.
  61. Coffin PO. National Drug Early Warning System (NDEWS) San Francisco Sentinel Community Site Drug Use Patterns and Trends, 2015. College Park, MD:NDEWS Coordinating Center. June 2015.
  62. Coffin PO. Naloxone for Opioid Safety. San Francisco Medicine: Journal of the San Francisco Medical Society. July/August 2015. 88(6):12-13.
  63. Coffin PO. Prevention of lethal opioid overdose in the community. UpToDate. 2015.
  64. Santos GM, Coffin P, Santos D, Huffaker S, Matheson T, Euren J, DeMartini A, Rowe C, Hahn JA, Vlahov D, Vittinghoff E, Batki SL. Feasibility, acceptability and tolerability of targeted naltrexone for non-dependent methamphetamine-using and binge-drinking men who have sex with men. Journal of Acquired Immunodeficiency Syndromes. 2015 Dec 15. [Epub ahead of print]. PMID:
  65. Rowe C, Santos GM, Behar E, Coffin PO. Correlates of overdose risk perception among illicit opioid users. Drug and Alcohol Dependence. 2015 Dec 30. pii: S0376-8716(15)01833-5. doi: 10.1016/j.drugalcdep.2015.12.018. PMID: 26754425.
  66. Cohen JK, Santos G-M, Moss NJ, Coffin PO, Block N, Klausner JD. Regular Clinic Attendance in Two Large San Francisco HIV Primary Care Settings. AIDS Care. 2015 Dec 11:1-6. DOI:10.1080/09540121.2015.1118431. PMID: 26654093.
  67. Banta-Green CJ, Coffin PO. Commentary on Pierce et al. (2016): Raising the bar of addiction treatment – first do no harm. Addiction. 2016 Feb;111(2):309-10. doi: 10.1111/add.13228. PMID: 26767339.
  68. Rowe C, Santos GM, Vittinghoff E, Wheeler E, Davidson P, Coffin PO. Spatial analysis of opioid overdose deaths and lay naloxone reversals as part of a community-based naloxone distribution program. Journal of Urban Health. 2016 Feb;93(1):117-130. Doi: 10.1007/s11524-015-0023-8. PMID 26800987.
  69. Rowe C, Matheson T, Das M, DeMicco E, Herbst JH, Coffin PO, Santos G-M. Correlates of recent HIV testing among substance-using men who have sex with men. International Journal of STD & AIDS. 2016. Mar 21. doi: 10.1177/0956462416640964. PMID: 27000299.
  70. Coffin PO, Rich J, Dailey M, Stancliff S, Beletsky L. While we dither, people continue to die from overdose: Comments on “Clinical provision of improvised nasal naloxone without experimental testing and without regulatory approval: imaginative shortcut or dangerous bypass of essential safety procedures?” Addiction. 2016 Jul 14. Doi: 10.1111/add.13412. PMID 27412566.
  71. Coffin PO, Rowe C. National Drug Early Warning System (NDEWS) San Francisco Sentinel Community Site Drug Use Patterns and Trends, 2016. College Park, MD:NDEWS Coordinating Center. June 2016.
  72. Coffin PO, Behar E, Rowe C, Santos G-M, Bald M, Coffa D, Vittinghoff E. Non-randomized intervention study of naloxone co-prescription for primary care patients on long-term opioid therapy for pain. Annals of Internal Medicine. 165(16). doi:10.7326/M15-2771. PMID 27366987.
  73. Rowe C, Santos GM, Coffin PO. Binge drinking concurrent with anal intercourse and condom use among men who have sex with men. AIDS Care. 2016 May 30: 1-5. PMID 27241085.
  74. Behar E, Rowe C, Santos G-M, Murphy S, Coffin PO. Primary Care Patient Experience with Naloxone Prescription. Annals of Family Medicine. Ann Fam Med. 2016 Sep;14(5):431-6. doi: 10.1370/afm.1972. PMID: 27621159.
  75. Behar E, Rowe C, Santos G-M, Coffa D, Turner C, Santos N, Coffin PO. Acceptability of naloxone co-prescription among primary care providers treating patients on long-term opioid therapy for pain. Journal of General Internal Medicine. 2016 Nov 4. doi: 10.1007/s11606-016-3911-z. PMID 27815762.
  76. Rowe C, Vittinghoff E, Santos G-M, Behar E, Turner C, Coffin PO. Performance measures of diagnostic codes for detecting opioid overdose in the emergency department. Academic Emergency Medicine. 2016 Oct 20. doi: 10.1111/acem.13121. PMID: 27763703.
  77. Wen LS, Goodwin KE, Coffin PO, Behar E. Promoting overdose prevention through policy, education, and outreach. NACCHO Exchange. 2016 Winter; 16(1):13-17.
  78. Behar E, Rowe C, Santos G-M, Santos N, Coffin PO. Academic detailing pilot for naloxone prescribing among primary care providers in San Francisco. Family Medicine. 2017 Feb;49(2):122-126. PMID: 28218937
  79. Turner CM, Coffin P, Santos D, Huffaker S, Matheson T, Euren J, DeMartini A, Rowe C, Batki S, Santos GM. Race/ethnicity, education, and age are associated with engagement in ecological momentary assessment text messaging among substance-using MSM in San Francisco. Journal of Substance Abuse Treatment. 2017 Apr;75:43-48. doi: 10.1016/j.jsat.2017.01.007. PMID 28237053.
  80. Rowe C, Santos GM, Raymond HF, Coffin PO. Social mixing and correlates of injection frequency among opioid use partnerships. International Journal of Drug Policy. 2017 Mar;41:80-88. Doi: 10.1016/j.drugpo.2016.11.016. PMID 28113118
  81. Hickman M. Grebely J, Bruneau J, Coffin P, Degenhardt L, Hutchinson S, Larney S, Martin N, Treloar C, Vickerman P. Editorial note to introduce HCV series: New developments and opportunities for preventing Hepatitis C Virus (HCV) among people who use and inject drugs – announcing an Addiction Series. Addiction. 2017 Jul;112(7):1126-1127. doi: 10.1111/add.13847. PMID: 28586551.
  82. Banta-Green C, Coffin PO, Schoeppe JA, Merrill JO, Whiteside LK, Ebersol AK. Heroin and pharmaceutical opioid overdose events: Emergency medical response characteristics. Drug and Alcohol Dependence. 2017 Sept:178:1-6. doi: 10.1016/j.drugalcdep.2017.04.021. PMID: 28623805.
  83. Fairbairn N, Coffin PO, Walley A. Naloxone for heroin, prescription opioid, and illicitly made fentanyl overdoses: challenges and innovations responding to a dynamic epidemic. International Journal of Drug Policy. 2017 Jul4. Pii: S0955-3959(17)30168-8. Doi: 10.1016/]j.drugpo.2017.06.005. PMID 28687187.
  84. Riley ED, Hsue PY, Vittinghoff E, Wu AHB, Coffin PO, Moore PK and Lynch KL. Higher prevalence of detectable troponin I among cocaine-users without known cardiovascular disease. Drug and Alcohol Dependence. 2017. Mar 1;172:88-93. doi: 10.1016/j.drugalcdep.2016.11.039. PMID: 28157591.
  85. Coffin PO, Santos G-M, Hern J, Vittinghoff E, Santos D, Matheson T, Colfax G, Batki S.L. Extended-Release Naltrexone for Methamphetamine Dependence among Men Who Have Sex with Men: A Randomized Placebo-Controlled Trial. Addiction. 2017. Jul 22. doi: 10.1111/add.13950. PMID: 28734107.
  86. Coffin PO, Santos G-M, Matheson T, Behar E, Rowe C, Rubin T, Silvis J, Vittinghoff E. Behavioral intervention to reduce opioid overdose among high-risk persons with opioid use disorder: a pilot randomized controlled trial. Plos One. October 2017;12(10):e0183354. doi: 10.1371/journal.pone.0183354. PMID: 29049282.
  87. Hall G. Koenig LJ, Gray SC, Herbst JH, Matheson T, Coffin P, Raiford J. Accuracy of HIV risk perceptions among Episodic Substance-Using Men who Have Sex with Men. AIDS and Behavior. 2017 Nov 4. DOI 10.1007/s10461-017-1935-y. PMID: 29103191.
  88. Bernadín SS, Rowe C, Behar E, Geier M, Washington S, Santos G-M, Euren J, Martin J, Gleghorn A, Coffin PO. Low-threshold extended-release naltrexone for high utilizers of public services with severe alcohol use disorder: A pilot study. Journal of Substance Abuse Treatment. 2017. pii: S0740-5472(16)30491-3. doi: 10.1016/j.jsat.2017.11.005. PMID: 29150316.
  89. Chou R, Korthuis PT, McCarty D, Coffin P, Griffin J, Davis-O’Reilly C, Grusing S, Daya M. Management of suspected opioid overdose with naloxone by emergency medical services personnel. Comparative effectiveness review. Agency for Healthcare Research and Quality, US Department of Health and Human Services. March 2017.
  90. Chou R, Korthuis PT, McCarty D, Coffin PO, Griffin J, Davis-O’Reilly C, Grusing S, Daya M. Management of suspected opioid overdose with naloxone in out-of-hospital settings: a systematic review. Annals of Internal Medicine. 2017. 28 November. DOI: 10.7326/M17-2224. PMID: 29181532
  91. Coffin PO, Rowe C. National Drug Early Warning System (NDEWS) San Francisco Sentinel Community Site Drug Use Patterns and Trends, 2017. College Park, MD:NDEWS Coordinating Center. December 2017.
  92. Hurstak E, Rowe C, Turner C, Behar E, Cabugao R, Lemos N, Coffin PO. Using medical examiner case narratives to improve opioid overdose surveillance. International Journal of Drug Policy. 2018 Jan 17;54:35-42. doi: 10.1016/j.drugpo.2017.12.017. PMID: 29353022.
  93. Banta-Green CJ, Coffin PO, Merrill JO, Sears JM, Dunn C, Floyd AS, Whiteside LK, Yanez ND, and Donovan DM (2018). Impacts of an opioid overdose prevention intervention delivered subsequent to acute care.Injury Prevention. 2018. Feb 7. pii: injuryprev-2017-042676. doi: 10.1136/injuryprev-2017-042676. PMID: 29353022.
  94. Rowe C, Vittinghoff E, Colfax G, Coffin PO, Santos G-M. Correlates of validity of self-reported methamphetamine use among a sample of dependent adults. Substance Use and Misuse. 20 Feb 2018. PMID: 29461134.
  95. Turner C, Chandrakumar D, Rowe C, Santos G-M, Riley ED, Coffin PO. Cross-sectional cause of death comparisons for stimulant and opioid mortality in San Francisco, 2005 – 2015. Drug and Alcohol Dependence. 21 Feb 2018. doi: 10.1016/j.drugalcdep.2017.12.030.